CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX) from its SEC filings: 2025 revenue $76.2 million (-45% vs the year before), net margin -23%, free cash flow -$75.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $76.2 million |
| Revenue growth | -45% |
| Net income | -$17.4 million |
| Net margin | -22.8% |
| Free cash flow | -$75.8 million |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -92% |
| Cash | $17.2 million |
| Long-term debt | $1.6 million |
| Share count, 1 year | +32% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.